MediLink's YL201 enters Phase 3 recruiting against chemo in esophageal cancer
The randomized trial testing the topoisomerase I stabilizer as a second-line option now recruiting patients sets up an overall survival readout against investigator's choice chemotherapy.
Executive Summary
- MediLink Therapeutics' Phase 3 trial of YL201 opened for recruitment after moving off Not yet recruiting status, with its enrollment target unchanged from plan.
- The randomized, open-label study pits the topoisomerase I stabilizer against investigator's choice chemotherapy in patients whose esophageal squamous cell carcinoma progressed on first-line therapy, with overall survival as the primary endpoint.
- Nine programs sharing the topoisomerase I target are in active development across tumor types and modalities, mostly antibody-drug conjugates, positioning this trial as the only Phase 3 small-molecule entrant testing the mechanism specifically in this indication.
- With no validated targeted second-line option for this cancer, a survival benefit that holds up against chemotherapy would be the result that distinguishes the mechanism in a disease area where recent trial activity has slowed.
The status change
The trial's registry status flipped from Not yet recruiting to Recruiting on July 16, 2026, with the enrollment target holding at 440 patients, the same figure set when the study first posted in March 2026. The change follows the trial's March 24, 2026 start date and reflects the study clearing its site-activation stage rather than any amendment to design. The primary completion date remains April 30, 2028, and full study completion is targeted for December 31, 2028. NCT07487896A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyNCT07487896
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The design
The study randomizes patients with locally advanced or metastatic esophageal squamous cell carcinoma who progressed after one line of systemic therapy to either YL201 or investigator's choice chemotherapy, an open-label, two-arm design with no masking. The primary endpoint is overall survival, measured from randomization to death from any cause over a window of up to approximately 36 months. Secondary endpoints include progression-free survival, objective response rate, disease control rate, duration of response, and adverse-event incidence, giving the trial a fuller efficacy and tolerability picture beyond the survival readout. Enrollment is confined to China across 81 sites, and eligibility requires ECOG performance status 0-1, at least one measurable lesion, and adequate organ function. NCT07487896A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyNCT07487896
The competitive field
Nine programs targeting topoisomerase I qualify as direct comparators to YL201, spanning Merck's pembrolizumab, Gilead's sacituzumab govitecan, Sichuan Kelun-Biotech's sacituzumab tirumotecan, and Sichuan Baili's BL-B01D1, among others, though most of these are antibody-drug conjugates tested in different tumor types rather than esophageal cancer specifically. Within esophageal squamous cell carcinoma itself, CSPC Megalith's SYS6010, a topoisomerase I-linked antibody-drug conjugate, is also in Phase 2/3 testing, making it the closest same-indication, same-target peer, though it differs from YL201 in modality. Field activity for the target has slowed markedly, with 62 recent trials against 825 older ones, a decline that reflects a mechanism class that has moved past its earliest exploratory phase into a smaller set of later-stage programs.
Operational read
The trial's enrollment target held flat at 440 patients against its own plan, a routine outcome that the sponsor's operational model flags only at moves of 20% or more. No protocol amendments to endpoints, eligibility criteria, or completion dates have been logged since the study posted, and MediLink runs 21 active trials across its pipeline with no terminations on record, indicating an experienced sponsor executing a standard site-activation sequence.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.